PATENT CLAIM ANALYSIS

Application Number: 15925013
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "468000"]

Abstract:
Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.

Claim (Index 46):
A method of treating neuropathic pain in a patient, comprising administering to the patient in need of such treatment one or more sustained release oral tablets comprising:\n (a) 10 wt % to 65 wt % of 1-{[\u03b1-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid; (b) 30 wt % to 50 wt % dibasic calcium phosphate; (c) 1 wt % to 50% of a release rate-modifying polymer; wherein wt % is based on the total dry weight of the dosage form, which tablet, when placed in 10 mM monobasic potassium phosphate buffer and 1% (wt/volume) sodium lauryl sulfate at pH 7.4 and 37\u00b0 C. and agitated at 50 rpm (USP, Type II), releases 20% of the 1-{[\u03b1-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid after 2 hours, 50% after 5 hours and 80% after 8 hours.

Metadata:
- Claim Count in Document: 95.0
- Percentile: 90.0
- Lexical Diversity: 1.17949
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14309662', '11269045', '15359321', '13164620', '14206893']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7603378165157055
- 35 USC 102 Novelty (BERT): 0.6245882827960432
- Combined Prediction Score: 0.7467628631437394
- Mean Citation Score: 496.648788
- Max Citation Score: 623.77496
- Similarity Product: 504.2685110692644

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test